|
 The trial compared the drug, pirfenidone, with a
placebo, and showed that after 52 weeks of treatment, 16.5 percent
of patients in the pirfenidone group experienced disease
progression, compared with 31.8 percent in the placebo group.
The disease, idiopathic pulmonary fibrosis (IPF), is an irreversible
condition that leads to progressive loss of lung function due to
scarring, which hinders the lungs' ability to absorb oxygen.
InterMune said it expected to submit a marketing application for the
drug to the U.S. Food and Drug Administration by early third quarter
of this year.
Trading in the company's shares was halted ahead of the
announcement. They closed at $13.96 on the Nasdaq on Monday.
(Reporting by Esha Dey in Bangalore;
editing by Sriraj Kalluvila)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
